NO20065012L - Tetrahydronaftyridin-derivater og fremgangsmate for fremstilling av disse - Google Patents

Tetrahydronaftyridin-derivater og fremgangsmate for fremstilling av disse

Info

Publication number
NO20065012L
NO20065012L NO20065012A NO20065012A NO20065012L NO 20065012 L NO20065012 L NO 20065012L NO 20065012 A NO20065012 A NO 20065012A NO 20065012 A NO20065012 A NO 20065012A NO 20065012 L NO20065012 L NO 20065012L
Authority
NO
Norway
Prior art keywords
processes
preparation
alkyl
compound
optionally substituted
Prior art date
Application number
NO20065012A
Other languages
English (en)
Inventor
Hitoshi Kubota
Yoshinori Nakamura
Takanori Higashijima
Yasuo Yamamoto
Kozo Oka
Shigeki Igarashi
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of NO20065012L publication Critical patent/NO20065012L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

Forbindelse med formel (I): hvor R1 er alkoksykarbonyl; R2 er alkyl; R3 er hydrogen; R4 er alkylen; R5 er en eventuelt substituert heterosyklisk gruppe; R6 , R7 og R8 er uavhengig av hverandre hydrogen, alkyl eller alkoksy; R10 er en eventuelt substituert aromatisk ring; eller et farmasøytisk akseptabelt salt av forbindelsen, som har en inhiberende aktivitet mot kolesterylestertransferprotein (CETP).
NO20065012A 2004-04-02 2006-11-01 Tetrahydronaftyridin-derivater og fremgangsmate for fremstilling av disse NO20065012L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004109551 2004-04-02
PCT/JP2005/006895 WO2005095395A2 (en) 2004-04-02 2005-04-01 Tetrahydronaphthyridine derivatives as cholesteryl ester transfer protein inhibitors

Publications (1)

Publication Number Publication Date
NO20065012L true NO20065012L (no) 2006-12-28

Family

ID=35064445

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065012A NO20065012L (no) 2004-04-02 2006-11-01 Tetrahydronaftyridin-derivater og fremgangsmate for fremstilling av disse

Country Status (18)

Country Link
US (1) US7781443B2 (no)
EP (1) EP1732924B1 (no)
JP (1) JP4633731B2 (no)
KR (1) KR100874623B1 (no)
CN (1) CN100441579C (no)
AR (1) AR048362A1 (no)
AU (1) AU2005228291B2 (no)
BR (1) BRPI0509588A (no)
CA (1) CA2560008C (no)
IL (1) IL178194A0 (no)
MX (1) MXPA06011416A (no)
MY (1) MY139887A (no)
NO (1) NO20065012L (no)
NZ (1) NZ550267A (no)
RU (1) RU2356902C2 (no)
TW (1) TWI345568B (no)
WO (1) WO2005095395A2 (no)
ZA (1) ZA200607782B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200601785A1 (ru) 2004-03-26 2007-02-27 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии
WO2006069162A1 (en) 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
DK1848430T3 (da) 2004-12-31 2017-11-06 Dr Reddys Laboratories Ltd Nye benzylamin-derivativer som cetp-inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
JP4681526B2 (ja) * 2005-09-29 2011-05-11 田辺三菱製薬株式会社 医薬組成物
RU2008119687A (ru) 2005-10-21 2009-11-27 Новартис АГ (CH) Комбинации органических соединений
US7652023B2 (en) 2005-11-23 2010-01-26 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7790770B2 (en) 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
UY30118A1 (es) * 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compueto amina trisustituido
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
MX2009010962A (es) 2007-04-13 2009-12-16 Kowa Co Compuesto pirimidina novedoso que tiene estructura de dibencilamina y medicamento que comprende el mismo.
AR069165A1 (es) * 2007-11-05 2010-01-06 Novartis Ag Derivados de 4-bencilamino-1-carboxacilpiperidina como inhibidores de cetp utiles para el tratamiento de hiperlipidemia
PT2404901E (pt) * 2007-12-03 2013-08-29 Novartis Ag Derivados de 4-benzilamino-pirrolidina 1,2-dissubstituídos como inibidores de cetp úteis para o tratamento de doenças tais como a hiperlipidemia ou a arteriosclerose
MX2011001887A (es) 2008-08-22 2011-04-04 Baxter Int Derivados de bencil carbonato polimericos.
CA2773038A1 (en) * 2009-09-04 2011-03-10 P. Jeffrey Conn Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
PL2604608T3 (pl) * 2009-11-27 2016-02-29 Adverio Pharma Gmbh Sposób wytwarzania {4,6-diamino-2-[1-(2-fluorobenzylo)-1H-pirazolo[3,4-b]pirydyn-3-ylo]pirymidyn-5-ylo}metylokarbaminianu metylu
CN103415511B (zh) * 2011-01-31 2016-01-20 国立大学法人长崎大学 光学活性化合物或其盐的制造方法
CA2845284C (en) 2011-08-18 2018-03-06 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholesteryl ester-transfer protein (cetp) inhibitors
JP6140168B2 (ja) 2011-09-27 2017-05-31 ドクター レディズ ラボラトリーズ リミテッド アテローム性動脈硬化症の処置のために有用なコレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての５−ベンジルアミノメチル−６−アミノピラゾロ［３，４−ｂ］ピリジン誘導体
WO2013103150A1 (ja) * 2012-01-06 2013-07-11 第一三共株式会社 置換ピリジン化合物の酸付加塩
CN104968345B (zh) 2012-01-19 2018-05-08 肿瘤疗法科学股份有限公司 1,5-萘啶衍生物和含1,5-萘啶衍生物的melk抑制剂
WO2014078778A2 (en) 2012-11-16 2014-05-22 Biocryst Pharmaceuticals, Inc. Antiviral azasugar-containing nucleosides
US20200077658A1 (en) 2016-12-16 2020-03-12 Basf Se Pesticidal Compounds
AU2018276192B2 (en) * 2017-05-30 2022-05-19 Dot Therapeutics-1, Inc. Method for producing optically active compound
CN107245074B (zh) * 2017-06-20 2019-04-09 牡丹江医学院附属红旗医院 用于治疗脑梗死的化合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
PL371416A1 (en) 2002-02-01 2005-06-13 Pfizer Products Inc. Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
EA200601785A1 (ru) * 2004-03-26 2007-02-27 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии

Also Published As

Publication number Publication date
AU2005228291A1 (en) 2005-10-13
MY139887A (en) 2009-11-30
RU2006138597A (ru) 2008-05-10
WO2005095395A3 (en) 2006-06-01
US20070032485A1 (en) 2007-02-08
EP1732924A2 (en) 2006-12-20
ZA200607782B (en) 2008-02-27
CN100441579C (zh) 2008-12-10
RU2356902C2 (ru) 2009-05-27
WO2005095395A2 (en) 2005-10-13
KR20060132966A (ko) 2006-12-22
EP1732924B1 (en) 2012-11-28
BRPI0509588A (pt) 2007-09-25
CA2560008A1 (en) 2005-10-13
AR048362A1 (es) 2006-04-19
NZ550267A (en) 2009-08-28
MXPA06011416A (es) 2006-12-20
CN1938301A (zh) 2007-03-28
CA2560008C (en) 2010-06-01
TW200536853A (en) 2005-11-16
KR100874623B1 (ko) 2008-12-17
IL178194A0 (en) 2006-12-31
US7781443B2 (en) 2010-08-24
JP4633731B2 (ja) 2011-02-16
JP2007530444A (ja) 2007-11-01
AU2005228291B2 (en) 2008-06-26
TWI345568B (en) 2011-07-21

Similar Documents

Publication Publication Date Title
NO20065011L (no) Tetrahydrokinolinderivater og fremgangsmate for fremstilling av disse
WO2005095395A3 (en) Tetrahydronaphthyridine derivatives as cholesteryl ester transfer protein inhibitors
JO2994B1 (ar) مثبطات البروتين الناقل لاستر الكولسترول ( cetp )
TW200605883A (en) Condensed heterocycle derivative having HCV inhibitory activity
WO2008111604A1 (ja) 新規なベンジル（ヘテロサイクリックメチル）アミン構造を有するピリミジン化合物及びこれを含有する医薬
DK1533292T3 (da) Dibenzylaminforbindelse og medicinsk anvendelse deraf
MX2009012283A (es) Derivado heterociclico que contiene nitrogeno que tiene actividad inhibitoria de 11beta-hidroxiesteroide-deshidrogenasa tipo 1.
JO2791B1 (en) Acid secretion inhibitor
NO20052469L (no) Inhibitorer av II-beta-hydroksysteroid-dehydrogenase type 1 og type 2.
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
NO20063446L (no) Tiazolderivater
NO20074071L (no) Hydrazinometyl, hydrozonometyl og 5-leddete heterocykliske forbindelser som virker som MTOR inhibitorer og anvendelse derav som anti-cancer midler
WO2008108380A3 (en) Pyrrole compounds
AU2003254852A8 (en) Fused heterocyclic compounds as peptidase inhibitors
EP1612204A4 (en) HYDRAZONE DERIVATIVE
NO331165B1 (no) Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme for fremstilling av medikamenter
NO20053133L (no) Kjemiske forbindelser.
NO20055921L (no) Heterocykliske metylsulfonderivater
NO20062617L (no) Anvendelse av glukosidase inhibitorer for terapi av mucovisidose
NO971687D0 (no) Diazepinoindoler som forsfodiesterase IV-inhibitorer
MX2010010471A (es) Derivado de tetrahidroisoquinolina novedoso.
UA86077C2 (en) Cetp inhibitors
ATE469156T1 (de) 3,4 diaminopyridin-derivate
NO20045540L (no) Nye 3-(4-okso-4H-kromen-2-yl)-(1H)-kinolin-4-on-forbindelser, en fremgangsmate for deres fremstilling og farmasoytisk sammensetninger inneholdende dem
UA84603C2 (ru) Производные тетрагидронафтиридина и способ их получения

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application